Milestone Achieved: First Pediatric Patient Dosed in LCA10 Gene Editing Trial

Milestone Achieved: First Pediatric Patient Dosed in LCA10 Gene Editing Trial

For the inherited retinal disease (IRD) community, particularly those affected by Leber congenital amaurosis 10 (LCA10), a significant development has occurred: the first pediatric patient has been dosed in a gene editing clinical trial. This news, reported by Ophthalmology Times Europe, marks a crucial step forward in the quest for treatments for this severe form of childhood blindness.

LCA10 is a rare genetic eye disorder that causes severe vision loss or blindness from birth or early infancy. It is considered the most common cause of inherited childhood blindness, affecting approximately two to three out of every 100,000 live births worldwide. Currently, there are no approved treatments for LCA10.

Key Facts from the Brilliance Clinical Trial

Editas Medicine Inc. announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the Brilliance clinical trial. This trial is designed to test the safety, tolerability, and efficacy of EDIT-101 for the treatment of LCA10, which is specifically related to CEP290 gene mutations. The company stated that this marks the world's first in vivo (inside the body) dosing of a pediatric patient with a CRISPR gene editing experimental medicine.

EDIT-101 is administered via a subretinal injection, a method intended to deliver the gene editing machinery directly to the photoreceptor cells in the eye. The Brilliance trial is a Phase 1/2 study, meaning it aims to assess both the safety and initial effectiveness of the treatment. Editas Medicine initiated enrollment in the pediatric mid-dose cohort after an Independent Data Monitoring Committee (IDMC) endorsed it, based on safety data from adult patients in the trial. EDIT-101 has received Rare Pediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), as well as Orphan Designation from the European Medicines Agency (EMA).

What This Means for Patients and Families

This development offers a beacon of hope for families affected by LCA10. The administration of an experimental CRISPR gene editing medicine to a pediatric patient represents a significant advancement in the field of inherited retinal diseases. While early, this step is critical for understanding the potential of gene editing to address genetic mutations that lead to severe vision impairment in children. The trial's focus on safety and initial efficacy data will be closely watched by the IRD community.

Looking Ahead

Editas Medicine is reportedly on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022 and expects to initiate testing of the pediatric high-dose later in the year. The company has expressed its anticipation of sharing future updates from the Brilliance trial, including additional clinical data. These upcoming updates will provide more insights into the potential of EDIT-101 as a treatment option for LCA10.